AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35761406 — intervention group
Group type: EXPERIMENTAL
Intervention: TB-T
Number of subjects: 0
Study 35761406 — intervention group
Group type: EXPERIMENTAL
Intervention: TB-T plus Valganciclovir
Number of subjects: 0
Study 35124474 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-layer silicone-adhesive polyurethane foam dressing
Number of subjects: 709
Study 35124474 — intervention group
Group type: COMPARATOR
Intervention: Standard preventive care alone
Number of subjects: 709
Study 32062494 — intervention group
Group type: COMPARATOR
Intervention: PG54 (n = 434), administered prostaglandin F2α (25 mg im) 7 days prior to TAI
Number of subjects: 1700
Study 32062494 — intervention group
Group type: EXPERIMENTAL
Intervention: PG72 (n = 426), same treatment as PG54 but TAI performed 72 ± 2 h after CIDR removal
Number of subjects: 1700
Study 32062494 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-CIDR54 (n = 422), same as PG54 but CIDR insert on Day -14
Number of subjects: 1700
Study 32062494 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-CIDR72 (n = 418), same as PG-CIDR54 but TAI performed 72 ± 2 h after CIDR removal
Number of subjects: 1700
Study 32062494 — intervention group
Group type: EXPERIMENTAL
Intervention: PG72
Number of subjects: 1700
Study 32062494 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-CIDR54
Number of subjects: 1700
Study 32062494 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-CIDR72
Number of subjects: 1700
Study 32062494 — intervention group
Group type: COMPARATOR
Intervention: PG54
Number of subjects: 1700
Study 35788519 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 30
Study 35788519 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study 34112285 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MAP group (LS group)
Number of subjects: 208
Study 34112285 — intervention group
Group type: COMPARATOR
Intervention: High MAP group (HS group)
Number of subjects: 208
Study 32759239 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT
Number of subjects: 176
Study 32759239 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT with biofeedback
Number of subjects: 176
Study 32759239 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT and rTMS
Number of subjects: 176
Study 32759239 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT with biofeedback and rTMS
Number of subjects: 176
Study 35790835 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-supported fluid quantifications
Number of subjects: 290
Study 35790835 — intervention group
Group type: COMPARATOR
Intervention: Conventional qualitative assessments (state-of-the-art disease management)
Number of subjects: 290
Study 35507901 — intervention group
Group type: EXPERIMENTAL
Intervention: IO bleaching only
Number of subjects: 40
Study 35507901 — intervention group
Group type: EXPERIMENTAL
Intervention: IO immediately after MA (IMA)
Number of subjects: 40
Study 35507901 — intervention group
Group type: EXPERIMENTAL
Intervention: IO seven days after MA (7MA)
Number of subjects: 40
Study 35507901 — intervention group
Group type: COMPARATOR
Intervention: no treatment (NC)
Number of subjects: 40
Study 32903044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation
Number of subjects: 363
Study 32903044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation (NYHA I/II)
Number of subjects: 363
Study 32903044 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy
Number of subjects: 363
Study 34358675 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 1135
Study 32368935 — intervention group
Group type: COMPARATOR
Intervention: BTB ACLR (Bone-Patellar Tendon-Bone Anterior Cruciate Ligament Reconstruction)
Number of subjects: 120
Study 32368935 — intervention group
Group type: EXPERIMENTAL
Intervention: BTB ACLR with LET (Lateral Extra-articular Tenodesis)
Number of subjects: 120
Study 32368935 — intervention group
Group type: COMPARATOR
Intervention: BTB ACLR
Number of subjects: 120
Study 32368935 — intervention group
Group type: EXPERIMENTAL
Intervention: BTB ACLR with LET
Number of subjects: 120
Study 34989143 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 39
Study 34989143 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 39
Study 33588856 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C8*2 or CYP2C8*3 allele carriers
Number of subjects: 618
Study 33588856 — intervention group
Group type: COMPARATOR
Intervention: CYP2C8*1/*1 wild type homozygotes
Number of subjects: 618
Study 32141968 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-trimester blood pressure trajectory parameters
Number of subjects: 3524
Study 35867584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-worn accelerometer
Number of subjects: 30
Study 35867584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower back, hip, thigh, and ankle accelerometers
Number of subjects: 30
Study 35867584 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist accelerometer
Number of subjects: 30
Study 35867584 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh and ankle accelerometers
Number of subjects: 30
Study 33293342 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-positive women (intervention)
Number of subjects: 1066
Study 33293342 — intervention group
Group type: COMPARATOR
Intervention: HPV-positive/cytology-negative women (control)
Number of subjects: 1066
Study 35704689 — intervention group
Group type: EXPERIMENTAL
Intervention: CBVR (Computer-Based Virtual Reality)
Number of subjects: 68
Study 35704689 — intervention group
Group type: EXPERIMENTAL
Intervention: PP (PowerPoint)
Number of subjects: 68
Study 35704689 — intervention group
Group type: COMPARATOR
Intervention: CBVR
Number of subjects: 68
Study 35704689 — intervention group
Group type: COMPARATOR
Intervention: PP
Number of subjects: 68
Study 32023544 — intervention group
Group type: EXPERIMENTAL
Intervention: ∼20‐min nap (N20)
Number of subjects: 9
Study 32023544 — intervention group
Group type: EXPERIMENTAL
Intervention: ∼90‐min nap (N90)
Number of subjects: 9
Study 32023544 — intervention group
Group type: COMPARATOR
Intervention: Normal Sleep Night (NSN)
Number of subjects: 9
Study 36094612 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuli's Cheetah heel cup
Number of subjects: 43
Study 36094612 — intervention group
Group type: COMPARATOR
Intervention: Tuli's The X Brace
Number of subjects: 43
Study 36094612 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study 33612314 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based sun protection program (SPP)
Number of subjects: 376
Study 33612314 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 376
Study 32013799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration <6 hours
Number of subjects: 2687
Study 32013799 — intervention group
Group type: COMPARATOR
Intervention: Sleep duration 6-8 hours (reference)
Number of subjects: 2687
Study 32013799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration >8 hours
Number of subjects: 2687
Study 33742738 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR after DCB angioplasty
Number of subjects: 208
Study 33742738 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion length
Number of subjects: 208
Study 33742738 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel caliber lumen diameter
Number of subjects: 208
Study 33742738 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR cut-off value
Number of subjects: 208
Study 34376401 — intervention group
Group type: EXPERIMENTAL
Intervention: CCP plus standard of care (SOC)
Number of subjects: 136
Study 34376401 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 136
Study 32183897 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured implementation of the patient guideline using a multimodal strategy
Number of subjects: 0
Study 32183897 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual with awareness of the patient guideline
Number of subjects: 0
Study 34618221 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise with breath-hold (IHG-BH)
Number of subjects: 20
Study 34618221 — intervention group
Group type: COMPARATOR
Intervention: Isometric handgrip exercise (IHG)
Number of subjects: 20
Study 34618221 — intervention group
Group type: COMPARATOR
Intervention: Breath-hold (BH)
Number of subjects: 20
Study 34800989 — intervention group
Group type: EXPERIMENTAL
Intervention: verum occipital tDCS treatment for 28 days
Number of subjects: 24
Study 34800989 — intervention group
Group type: COMPARATOR
Intervention: sham occipital tDCS treatment
Number of subjects: 24
Study 32316911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (10 to 40 mg/day)
Number of subjects: 30
Study 32316911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 36148077 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - three 5-min cycles of inflation and deflation of blood pressure cuff on the upper limb
Number of subjects: 120
Study 36148077 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 120
Study 36148077 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 33531059 — intervention group
Group type: EXPERIMENTAL
Intervention: Met/Cyslow + PUFA
Number of subjects: 14
Study 33531059 — intervention group
Group type: COMPARATOR
Intervention: Met/Cyshigh + SFA
Number of subjects: 14
Study 33531059 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 33177731 — intervention group
Group type: EXPERIMENTAL
Intervention: Early interventional rehabilitation training (2-7 days after onset)
Number of subjects: 82
Study 33177731 — intervention group
Group type: COMPARATOR
Intervention: Delayed rehabilitation training (3-4 weeks after onset)
Number of subjects: 82
Study 34857640 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic dextrose gel
Number of subjects: 165
Study 34857640 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 165
Study 34857640 — intervention group
Group type: COMPARATOR
Intervention: No gel (controls)
Number of subjects: 165
Study 36150741 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 80
Study 36150741 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline placebo
Number of subjects: 80
Study 35966875 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg daily for 56 weeks
Number of subjects: 120
Study 35966875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33319932 — intervention group
Group type: EXPERIMENTAL
Intervention: Get going After concussIoN (novel behavioral intervention)
Number of subjects: 42
Study 33319932 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 42
Study 34609058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandwich osteotomy with simultaneous implant placement using patient-specific guides (PSGs)
Number of subjects: 12
Study 34609058 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (free-hand sandwich osteotomy)
Number of subjects: 12
Study 32239737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve stimulator-guided injection with methylprednisolone/lidocaine
Number of subjects: 20
Study 32239737 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) injection
Number of subjects: 20
Study 35772449 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 booster
Number of subjects: 261
Study 35772449 — intervention group
Group type: COMPARATOR
Intervention: PHiD-CV10 booster
Number of subjects: 261
Study 33740736 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel, applied twice weekly for 3 weeks
Number of subjects: 90
Study 33740736 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing with silver sulfadiazine ointment, applied twice daily
Number of subjects: 90
Study 36039026 — intervention group
Group type: EXPERIMENTAL
Intervention: Scores of 4 to 8 points
Number of subjects: 932
Study 36039026 — intervention group
Group type: EXPERIMENTAL
Intervention: Scores >8 points
Number of subjects: 932
Study 36039026 — intervention group
Group type: EXPERIMENTAL
Intervention: Scores of 4 to 8 points in validation score (70%)
Number of subjects: 932
Study 36039026 — intervention group
Group type: EXPERIMENTAL
Intervention: Scores >8 points in validation score (70%)
Number of subjects: 932
Study 36039026 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual recipient factors with 4 to 8 points
Number of subjects: 932
Study 36039026 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual recipient factors with scores >8 points
Number of subjects: 932
Study 32038000 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress (HS) conditions (moderate THI = 81 to 83; severe THI = 88 to 90)
Number of subjects: 16
Study 32038000 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral (TN) conditions (ambient temperature 22°C for 7 days)
Number of subjects: 16
Study 32038000 — intervention group
Group type: EXPERIMENTAL
Intervention: High THI levels
Number of subjects: 16
Study 32038000 — intervention group
Group type: COMPARATOR
Intervention: Low THI levels
Number of subjects: 16
Study 32038000 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress (HS) period
Number of subjects: 16
Study 34538564 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevation Training Mask® 2.0 (ETM)
Number of subjects: 10
Study 34538564 — intervention group
Group type: COMPARATOR
Intervention: Sham control condition
Number of subjects: 10
Study 36136304 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib + Temozolomide
Number of subjects: 40
Study 36136304 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib + Irinotecan
Number of subjects: 40
Study 34383511 — intervention group
Group type: EXPERIMENTAL
Intervention: Training middle managers to enact psychosocial safety climate (PSC) in work units for 8 months.
Number of subjects: 531
Study 34383511 — intervention group
Group type: EXPERIMENTAL
Intervention: Training middle managers to enact PSC in work units.
Number of subjects: 531
Study 34383511 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 531
Study 32543876 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Physical Therapy (MPT)
Number of subjects: 47
Study 32543876 — intervention group
Group type: COMPARATOR
Intervention: Conventional Pharmacologic Treatment (CPT)
Number of subjects: 47
Study 34720019 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg) tablet given twice a day for two months
Number of subjects: 80
Study 34720019 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine added to the culture medium during IVF (PCO-clonidine group)
Number of subjects: 80
Study 34720019 — intervention group
Group type: COMPARATOR
Intervention: Clonidine added to the culture medium during IVF (egg donors-clonidine group)
Number of subjects: 80
Study 34720019 — intervention group
Group type: COMPARATOR
Intervention: Clonidine added to the culture medium during IVF (PCO-without group)
Number of subjects: 80
Study 35025153 — intervention group
Group type: EXPERIMENTAL
Intervention: EA + biofeedback
Number of subjects: 60
Study 35025153 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 60
Study 35025153 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 60
Study 33682556 — intervention group
Group type: EXPERIMENTAL
Intervention: ZSP1601 (25 to 350 mg single ascending dose)
Number of subjects: 100
Study 33682556 — intervention group
Group type: EXPERIMENTAL
Intervention: ZSP1601 (50 or 100 mg QD multiple ascending doses)
Number of subjects: 100
Study 33682556 — intervention group
Group type: EXPERIMENTAL
Intervention: ZSP1601 (100 mg)
Number of subjects: 100
Study 33682556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32274634 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (2 ng/ml)
Number of subjects: 422
Study 32274634 — intervention group
Group type: COMPARATOR
Intervention: Control medium
Number of subjects: 422
Study 616788547 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + L-carnitine
Number of subjects: 60
Study 616788547 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Omega-3
Number of subjects: 60
Study 616788547 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Omega-3 + L-carnitine
Number of subjects: 60
Study 616788547 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine + Omega-3
Number of subjects: 60
Study 616788547 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Placebo
Number of subjects: 60
Study 616788547 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 36300997 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based genital hygiene education
Number of subjects: 62
Study 36300997 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study 34463631 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic authentication strategies
Number of subjects: 624
Study 34463631 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual authentication strategies
Number of subjects: 624
Study 32445969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclist positioned closer to the centre of the lane with a shorter time gap to the oncoming vehicle (6 seconds)
Number of subjects: 0
Study 32445969 — intervention group
Group type: COMPARATOR
Intervention: Cyclist positioned further from the centre of the lane with a longer time gap to the oncoming vehicle (9 seconds)
Number of subjects: 0
Study 32445969 — intervention group
Group type: EXPERIMENTAL
Intervention: Female drivers' overtaking strategy
Number of subjects: 0
Study 35065662 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of intravenous (IV) phenobarbital (7.5 mg/kg of ideal body weight)
Number of subjects: 39
Study 35065662 — intervention group
Group type: COMPARATOR
Intervention: Single dose of matching IV placebo
Number of subjects: 39
Study 32769633 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg twice daily
Number of subjects: 0
Study 32769633 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily
Number of subjects: 0
Study 35195752 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinator-based intervention (Liaison Intervention - LI)
Number of subjects: 141
Study 35195752 — intervention group
Group type: COMPARATOR
Intervention: Non-Liaison Intervention (non-LI)
Number of subjects: 141
Study 35195752 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary fractures
Number of subjects: 141
Study 35038578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy (CSP)
Number of subjects: 123
Study 35038578 — intervention group
Group type: COMPARATOR
Intervention: Cold biopsy forceps (CBF)
Number of subjects: 123
Study 32584426 — intervention group
Group type: EXPERIMENTAL
Intervention: adavosertib (SUKSES-C)
Number of subjects: 286
Study 32584426 — intervention group
Group type: EXPERIMENTAL
Intervention: vistusertib (SUKSES-D)
Number of subjects: 286
Study 32584426 — intervention group
Group type: EXPERIMENTAL
Intervention: adavosertib (SUKSES-N1)
Number of subjects: 286
Study 32584426 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2811NP (SUKSES-N3)
Number of subjects: 286
Study 32584426 — intervention group
Group type: COMPARATOR
Intervention: Control group (SUKSES-C and SUKSES-N1)
Number of subjects: 286
Study 32584426 — intervention group
Group type: COMPARATOR
Intervention: Control group (SUKSES-D)
Number of subjects: 286
Study 35099501 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA-authorized instructions
Number of subjects: 338
Study 35099501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention instructions (decision science principles)
Number of subjects: 338
Study 35099501 — intervention group
Group type: COMPARATOR
Intervention: Control (no instructions)
Number of subjects: 338
Study 34400314 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs)
Number of subjects: 0
Study 34400314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-dose ICS without use of background controller
Number of subjects: 0
Study 34400314 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed ICS dosing
Number of subjects: 0
Study 33549081 — intervention group
Group type: EXPERIMENTAL
Intervention: Overminus lenses of -2.50 D with 2 PD base-in prisms
Number of subjects: 60
Study 33549081 — intervention group
Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 60
Study 32912290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (50 mg BID)
Number of subjects: 132
Study 33487257 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (300 g/d)
Number of subjects: 44
Study 33487257 — intervention group
Group type: COMPARATOR
Intervention: Regular yogurt (300 g/d)
Number of subjects: 44
Study 34080761 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal Imitation Training (RIT)
Number of subjects: 66
Study 34978712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention with strength framing
Number of subjects: 616
Study 34978712 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention with strength framing
Number of subjects: 616
Study 34978712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention with weakness framing
Number of subjects: 616
Study 34978712 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention with weakness framing
Number of subjects: 616
Study 33714703 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular dressing group (RD) - dressings changed every week regularly and additionally when oozing was noticed.
Number of subjects: 197
Study 33714703 — intervention group
Group type: COMPARATOR
Intervention: Non-regular dressing group (ND) - dressings changed only when oozing was visible.
Number of subjects: 197
Study 33714703 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular dressing group (RD)
Number of subjects: 197
Study 33714703 — intervention group
Group type: COMPARATOR
Intervention: Non-regular dressing group (ND)
Number of subjects: 197
Study 32607569 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral hydration (ice chips and water) after extubation
Number of subjects: 149
Study 32607569 — intervention group
Group type: COMPARATOR
Intervention: Usual care (a 6-hour fast)
Number of subjects: 149